Paper Title
A Review on Therapeutic Applications of GSK-3 beta Inhibitors
Article Identifiers
: Keywords
Glycogen Synthase Kinase 3 Beta (GSK 3 Beta), Indazole Derivatives, GSK 3 Beta Inhibitors, Cancer, Alzheimer’s Disease, Diabetes
Abstract
Abstract : Glycogen synthase kinase 3 beta (GSK-3 beta), which is a serine/threonine kinase was initially identified because of its key role in the regulation of glycogen synthesis. But it is now well-established that GSK-3 performs critical functions in many cellular processes, such as apoptosis, tumor growth, cell invasion, and metastasis. Many human disorders, including cancer, have been linked to abnormal GSK-3 activity, underlining its therapeutic promise as a cancer target. [29]. There is conflicting evidence on the effect of GSK-3 inhibition on cancer cell development due to multiple methods through which GSK-3 may influence carcinogenesis. It can act as a tumor promoter as well as a tumor suppressor in different types of cancers [14]. However, it is found that combination of GSK-3 beta inhibitors with chemotherapeutic agents can significantly reduce the resistance of various tumor cells towards the chemotherapy. In the last few years, many GSK-3 inhibitors have been developed, and some are currently being tested in clinical trials [16]. Indazoles are nitrogen-based heterocyclic chemicals that posses many types of biological activities and representatives of this class of pharmacological agents are widely used as antibacterial, anti-inflammatory, anti-HIV, Antiprotozoal and antimalarial agents. Recent studies are showing promising activity of indazole derivatives as anticancer agents.
Downloads
How To Cite (APA)
Anu Jayamol Mathew, Aiswarya Suresh, Anu Yousef, & Dr. Deepa Jose (March-2022). A Review on Therapeutic Applications of GSK-3 beta Inhibitors. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 7(3), 94-103. https://ijnrd.org/papers/IJNRD2203010.pdf
Issue
Volume 7 Issue 3, March-2022
Pages : 94-103
Other Publication Details
Paper Reg. ID: IJNRD_180575
Published Paper Id: IJNRD2203010
Downloads: 000122257
Research Area: Pharmacy
Author Type: Indian Author
Country: Ernakulam, Kerala, India
Published Paper PDF: https://ijnrd.org/papers/IJNRD2203010.pdf
Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2203010
About Publisher
Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)
UGC CARE JOURNAL PUBLICATION | ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG
Copyright & License
© 2025 — Authors hold the copyright of this article. This work is licensed under a Creative Commons Attribution 4.0 International License. and The Open Definition.
You are free to share, adapt, and redistribute the material, provided proper credit is given to the original author. 🛡️ Disclaimer: The content, data, and findings in this article are based on the authors’ research and have been peer-reviewed for academic purposes only. Readers are advised to verify all information before practical or commercial use. The journal and its editorial board are not liable for any errors, losses, or consequences arising from its use.
Publication Timeline
Article Preview: View Full Paper
Call For Paper
IJNRD is a Scholarly Open Access, Peer-Reviewed, Refereed, and UGC CARE Journal Publication with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost, and Transparent Peer Review Journal Publication that adheres to the UGC CARE 2025 Peer-Reviewed Journal Policy and aligns with Scopus Journal Publication standards to ensure the highest level of research quality and credibility.
IJNRD offers comprehensive Journal Publication Services including indexing in all major databases and metadata repositories, Digital Object Identifier (Crossref DOI) assignment for each published article with additional fees, citation generation tools, and full Open Access visibility to enhance global research reach and citation impact.
The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse academic and professional fields. The journal promotes global knowledge exchange among researchers, developers, academicians, engineers, and practitioners, serving as a trusted platform for innovative, peer-reviewed journal publication and scientific collaboration.
Indexing Coverage: Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many other recognized academic repositories.
How to submit the paper?
By Our website
Click Here to Submit Paper Online
You can now publish your research in IJNRD. IJNRD is a Transparent Peer-Reviewed Open Access Journal Publication (Refereed Journal), aligning with New UGC and UGC CARE recommendations.
For more details, refer to the official notice: UGC Public Notice
Submit Paper Online
Important Dates for Current issue
Paper Submission Open For: December 2025
Current Issue: Volume 10 | Issue 12 | December 2025
Impact Factor: 8.76
Last Date for Paper Submission: Till 31-Dec-2025
Notification of Review Result: Within 1-2 Days after Submitting paper.
Publication of Paper: Within 01-02 Days after Submititng documents.
Frequency: Monthly (12 issue Annually).
Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.
Subject Category: Research Area
Call for Paper: More Details
Approval, Licenses and Indexing: More Details
